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The presence of apolipoprotein-c4 (APOE- 
€4)  significantly increases the risk of 
Alzheimer's disease (AD). The association 
between A P O E - E ~  status and functional 
abilities was explored further in a multicul- 
tural sample of community-dwelling, non- 
demented elders. The sample was limited to 
cognitively-intact, community-dwelling el- 
ders, who were free of stroke or other neu- 
rologic disability. In 218 elders who met re- 
search criteria, the presence of A P O - E ~  was 
associated with poorer functional status, 
apart from the effects of neuropsychological 
performance, gender, age, and education 
(OR = 2.5, 95% CI: 1.3, 4.9). In 158 subjects 
without an A P O E - E ~  allele, 50% reported no 
functional limitation; in the 60 subjects with 
an €4 allele, only 28% reported no functional 
limitation (P c .01). The relationship was 
not explained by the distribution of co-mor- 
bidities. The association between poorer 
function and the presence of an A P O E - E ~  al- 
lele was evident in each ethnic group. In 
path analyses, the presence of an APOE-€4 
allele was associated with decreased func- 
tional ability in non-demented elders not 
simply through an association with poorer 
cognitive status, but also independently. 
These results suggest that the APOE-el 
genotype is associated with functional 
deficit in people with normal neuropsycho- 
logical profiles. 0 1995 Wiley-Liss, Inc. 
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INTRODUCTION 
The prevalence of an  APOE-E4 allele is increased 
among patients with Alzheimer's disease (AD), both 
sporadic and familial, compared to controls.'-9 The lo- 
cation of APOE on chromosome 19q13.2, an area al- 
ready linked to late-onset familial AD,'' strengthens 
the plausibility of this relationship. In addition, APOE- 
E4 alleles were found to be less frequent than other 
polymorphisms in centenarians, suggesting a relation- 
ship to longevity," as  confirmed by studies relating 
APOE-el to congestive heart disease" and ischemic 
cerebrovascular disease.13 
We explored potential associations between APOE 
status and function in non-demented elders. Because 
these elders are living in the community and are, for 
the most part, healthy, we suspected that APOE status 
might affect high-level functional status, as  assessed by 
self-ratings of competence in performing tasks associ- 
ated with independent living. 
METHODS AND MATERIALS 
Subjects 
Subjects in this study were non-demented elders free 
of dementia from a community study in northern Man- 
hattan, New York; all received clinical assessments 
that included neuropsychological testing. The subjects 
are representative of community-dwelling, non-de- 
mented elders who use health services and were re- 
cruited without regard to genotype or functional status. 
The 218 subjects assessed in this study were re- 
cruited from three sources: a population-based commu- 
nity survey of a random sample of elders (n = 97), a 
community registry of people who sought medical or so- 
cial services (n = 93), and people who had been as- 
sessed at the Columbia-Presbyterian Memory Disor- 
ders Clinic (n = 28). The three groups did not 
significantly differ in sociodemographic features or  
neuropsychological performance. Nor did the distribu- 
tion of APOE genotypes differ between the groups. The 
age range of subjects was 58-93 years. 
Definition and Assessment of Healthy Elders 
None of the subjects met DSM-I11 (3rd Edition, Re- 
vised) criteria for dementia, and those with stroke, de- 
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pression, or Parkinson’s disease were excluded. A stan- 
dardized neuropsychological battery was used to assess 
cognitive performance. Using a set of previously de- 
scribed cut scores,14 neuropsychological performance on 
the battery was summarized according to whether sub- 
jects had no or only one low test score (“no cognitive 
deficit, no apparent clinical significance”), or low scores 
on two or more tests (“low test scores with possible clin- 
ical significance”). Subjects with low scores on more 
than two tests who also had functional deficits exten- 
sive enough to warrant the label of “questionable de- 
mentia” (equivalent to a Clinical Dementia Rating15 
score of 0.5) were excluded. Because of its sensitivity to 
early stages of dementing disease, additional analyses 
were conducted with the Selective Reminding Test 
(SRT, total and delayed recall),16’ l7 one of the 15 tests in 
the battery. 
Functional Outcomes 
Functional status was assessed with the Schwab and 
England Activities of Daily Living scale,” the Blessed 
Dementia Rating Scale (BDRS, Part  I),” and the 
Barthel index2’ The Schwab and England ADL scale is 
a measure of self-reported overall independence in 
functional activities. This modified visual analogue 
scale ranges from 0 (bedridden) to 100% (completely in- 
dependent) in increments of 10%; each decile is an- 
chored to behavioral descriptions indicating degree of 
difficulty with activities and need for help. The BDRS 
assesses performance in the activities of daily living 
(ADL) as well as self-perceived cognitive status. The 
Barthel function items assess need for help in ADLs. 
Both scales were summed to form composites of 11 and 
7 items, respectively. 
Medical histories and sociodemographic information 
were also obtained. Racial-ethnic assignment of sub- 
jects followed the format used in the 1990 Census.” 
DNA Allelotyping 
The procedure for DNA allelotypinE at the APOE lo- 
cus has been previously described. Data regarding 
APOE genotypes were shielded from investigators. 
Data Analyses 
Allelic frequencies for subjects were determined. The 
sample was divided according to those with no APOE- 
E4 allele (n = 158) and those with one or two alleles (n 
= 60). The small number of subjects homozygous for 
APOE-E4 (n = 4) precluded analysis of these subjects as  
separate group. Univariate analyses explored whether 
the two genotype groups differed in sociodemographic 
features, distribution of comorbidities, neuropsycholog- 
ical status, and functional outcomes. To control for po- 
tential confounders, multivariate logistic models were 
used. In these models, the primary outcome was func- 
tional ability on the Schwab & England measure, which 
was dichotomized to compare those reporting no func- 
tional impairment (score of 100) with those reporting 
any deficit (score < 100). Alternative cutpoints for this 
measure were also assessed. 
In addition, a causal model using path analysisz2 was 
developed to assess relationships between APOE-E4 
status, neuropsychological performance, and functional 
ability. The path model enables one to assess the extent 
to which APOE status may affect functional status di- 
rectly and also indirectly through its association with 
neuropsychological performance. 
RESULTS 
Characteristics of Study Sample 
Allelic frequencies for the sample, stratified by eth- 
nicity, are shown in Table I. Consistent with previous 
observations,’ African-Americans had the highest fre- 
quency of APOE-E4 alleles (22%), compared to 9% 
among Caucasians and 12% among Hispanics. 
Sociodemographic and other characteristics of the 
sample, by APOE status, are shown in Table 11. Gender, 
age, and education did not differ according to APOE-E4 
status. Also, APOE-E4 status was not related to neu- 
ropsychological status; the proportion of people with 
low scores on the neuropsychological battery was 
roughly the same in the APOE-E4 groups, and memory 
performance as  assessed by mean SRT scores did not 
differ. 
Examination of medical histories showed that the 
groups did not significantly differ in the prevalence of 
12 medical conditions. Also, they did not differ in total 
number of medical conditions, medications, or surgical 
procedures reported. 
APOE-E4 and Functional Ability 
Table I1 shows that subjects with one or more APOE- 
E4 alleles reported significantly poorer scores on mea- 
sures assessing high-level function. Mean scores on the 
Schwab & England ADL self-rating were significantly 
lower among subjects with APOE-E4 (87.3 vs. 80.9, P < 
.05). Half (50%) of the non-APOE-E4 group reported 
complete independence in ADL tasks, compared to only 
28% among those with an  APOE-E4 allele (P  < .01). 
In a multivariate logistic regression model, in which 
age, gender, education, and neuropsychological mea- 
sures were entered, APOE-E4 status remained a signif- 
icant predictor of functional deficit (OR = 2.5, 95% CI: 
1.3, 4.9). In this model, age was the only other signifi- 
cant predictor. The groups significantly differed in 
Schwab & England scores when the scale was di- 
chotomized at lower levels of functional ability (70, 80, 
and 90% of optimal function). The complete distribu- 
tion of Schwab & England scores for each group is 
shown in Figure 1. 
Subjects with the APOE-E4 genotype reported more 
impairment on the Blessed Dementia Rating Scale 
summary score as  well. The poorer score is largely due 
to greater reported difficulty with tasks involving mem- 
ory. For example, 44% of people with the APOE-E4 
TABLE I. Apo-E Allelic Frequencies, by Ethnicitv” 
e2 e3 e4 
Caucasian (n = 43) .06 .85 .09 
African-American (n = 62) .07 .71 .22 
Hispanic (n = 96) .04 .84 .12 
* n = 201 (ethnicity unknown in 12 subjects) 
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TABLE 11. Comparison of Non-Demented Elders, 
bvApo-e4 Status 
No e4 Allele 
(n = 158) 
2 1 e4 Allele 
(n = 60) 
Sociodemographics 
Gender (% female) 
Age (years) 
Education (highest grade of school) 
SRT total recall 
SRT delayed recall 
Low score 2 2  tests, 
Schwab & England* 
Blessed Dementia Rating Scale 
Barthel Index 
Neuropsychological status 
neuropsychological battery (%) 
Functional Status 
No ADL impairment (%)** 





















* P < .05; ** P < .01. No ADL impairment indicated by score of 100 on Schwab & 
England scale. SRT, Selective Reminding Test. 
genotype reported at least some difficulty with memory 
for lists, compared to only 25% among those without 
the APOE-el genotype. However, the association be- 
tween APOE- 4 and functional independence remained 
significant even when entering this memory item into 
the logistic model (OR = 2.2; 95% CI: 1.1, 4.5). Mea- 
sures of more severe functional disability, as assessed 
by the Barthel scale, did not differ by APOE-4 status. 
Table I11 presents allele frequencies for subjects with 
and without any ADL deficit (as assessed by a score of 
100 on the Schwab & England measure), stratified by 
ethnicity. In each ethnic group, subjects reporting 
poorer function had a higher frequency of APOE-4 
alleles. Also, subjects with the APOE-E2 genotype 
( ~ 2 / ~ 2 ,  ~ 2 / ~ 3 )  were more likely to be completely inde- 
pendent in ADL function (OR = 2.6; 95% CI: 1.3, 5.0). 
Logistic regression analyses showed that the pres- 
ence of one or more APOE-el alleles is associated with 
poorer function in each ethnic group (odds ratio for 
Caucasians 1.9, African-Americans 1.6, and Hispanics 
6.9); however, owing to small sample sizes, these re- 
sults achieved statistical significance only in the His- 
panic sample. 
Finally, a path analysis was conducted to test 
whether A P O E - E ~  status was associated with poorer 
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ADL (%) by Subject 
Fig. 1. ADL (%I by Apo-El status, non-demented subjects. 
586 Albert et al. 
TABLE 111. Distribution of Apo-E Genotypes Among Non-Demented Elders, by Ethnicity and Functional Status” 
Apo-E genotypes Allele frequency 
313 213 314 41 4 41 2 21 2 Apo-e3 Apo-e4 Apo-e2 
Caucasian 
<loo% ADL (n = 19) 14 1 2 1 1 0 .82 .13 .05 
100% ADL (n = 24) 18 3 3 0 0 0 .88 .06 .06 
<loo% ADL (n = 39) 18 3 16 1 1 0 .72 24 .04 
100% ADL (n = 23) 11 3 8 0 0 1 .72 .17 .ll 
<loo% ADL (n = 53) 34 1 15 2 1 0 .79 .19 .02 
100% ADL (n = 43) 36 3 3 0 0 1 .91 .03 .06 
African-American 
Hispanic 
* 100% ADL indicates score of 100 on Schwab & England scale (“completely independent; able to  do all chores without slowness, difficulty, or 
impairment”). n = 201 (ethnicity unknown in 12 subjects). 
poorer cognitive performance. The model shows that 
APOE-E4 is associated with poorer functional status in 
two ways: 1) through a weak association with lower 
performance on neuropsychological measures (r = .06, 
NS), which in turn are associated with poorer func- 
tional status (r = .20, P = ,003); and 2) through an  in- 
dependent effect on functional status (r = .16, P = .02). 
That is, within each level of neuropsychological perfor- 
mance (as assessed by battery performance or SRT 
score), subjects with one or more APOE-€4 alleles still 
reported poorer functional status. 
DISCUSSION 
Our data suggest that the APOE-E4 genotype is asso- 
ciated with poorer functional status among non- 
demented, community-dwelling elders. This relation- 
ship was observed in all three ethnic groups, though 
small sample sizes require that this finding be replicated 
in other studies. The relationship between genotype and 
functional status does not appear to be an artifact of 
other differences between the genotypes that may be cor- 
related with functional status, such as  the distribution of 
age, gender, or education; neuropsychological perfor- 
mance; or co-morbid conditions and service utilization. 
The genotype groups did not differ in measures of 
more severe functional deficit (e.g., the Barthel mea- 
sure), but rather in reports of general functional ability. 
Here differences are large: 50% of the non-APOE-E4 
group reported complete independence in ADLs com- 
pared to only 28% among those with APOE-E4 allele. 
The association between APOE-E4 and more subtle 
deficits is reasonable because subjects in this study 
were explicitly ascertained as  healthy elders; all were 
residing in the community, and all were free of clini- 
cally significant cognitive deficit. Thus, it might be ex- 
pected that elders in the sample would not show the se- 
vere functional deficits assessed in the Barthel 
measures of disability. 
Having established a relationship between APOE 
and functional ability in this sample, two questions 
need to be addressed. First, is the association between 
APOE-E4 and poorer function artifactual, or does the 
association demonstrate a true independent genetic ef- 
fect? Second, what biologic mechanism, if any, could 
account for this effect? 
With regard to the first question, the increased risk 
of functional deficit may indicate a genetic effect. Con- 
founding factors were controlled in these analyses (e.g., 
sociodemographic variation, comorbid conditions, and 
neuropsychological status), reducing the likelihood 
that the observed association is spurious. Also, the as- 
sociation was found among each of the ethnic groups, 
an  important finding given differences in allelic fre- 
quencies across the groups. The significant association 
between APOE-E4 status and functional outcomes in 
models that control for differences in neuropsychologi- 
cal profile suggests an independent effect of this geno- 
type on functional status. While the genotype groups 
did not differ in neuropsychological profiles (as as- 
sessed by a general neuropsychological battery, includ- 
ing a test notable for sensitivity to early effects of de- 
mentia), people with APOE-E4 did report poorer 
function in BDRS tasks involving memory (e.g., ability 
to remember lists). However, A P O E - E ~  status was a sig- 
nificant, independent predictor of functional status in 
logistic regression models that included BDRS memory 
items. This, combined with the path model results, is 
evidence that APOE-E4 and cognitive status each inde- 
pendently increase the risk that functional ability may 
be impaired in nondemented elders. 
Turning to the question of a mechanism for this ge- 
netic effect, it should be noted that subjects with an 
APOE-E4 allele in this sample may or may not go on to 
develop Alzheimer’s disease; conversely, some of the 
subjects without an APOE-E4 allele may also develop 
dementia. The association between APOE genotype 
and functional ability reported here may involve mech- 
anisms distinct from those postulated to explain the in- 
creased risk of Alzheimer’s disease associated with this 
genotype. The question remains open. Our findings 
should be seen in the light of other research that shows 
an effect of APOE-E4 on measures of cognitive status 
and brain function in nondemented elders. For exam- 
ple, Feskins e t  al.23 and Reed et al.24 reported signifi- 
cant associations between APOE allelic status and cog- 
nitive performance, while Small et al.25 found a 
significant association between APOE-E4 and measures 
of cerebral metabolic rate. Longitudinal follow-up to de- 
tect onset of dementia is required, in our research as 
well as  in these studies, to determine if these associa- 
tions represent early manifestations of pathophysiolog- 
ical processes typical of Alzheimer’s disease or some 
other process more directly linked to APOE-E4 protein 
levels, as suggested by Poirier.26 
Finally, compared to other Caucasian populations (in 
which A P O E - E ~  frequencies range from 12-15%), the 
APOE-E4 allelic frequency in this sample is low. The 
low frequency may reflect the high incidence of 
Alzheimer’s disease at  this age among Caucasians with 
€41~4 and €31~4  genotype^.^' However, in the cross-sec- 
tional design adopted here, this selection effect does not 
bias associations between genotype and functional out- 
come. Also, the high frequency of APOE-E4 alleles in 
the African-American sample is notable; Hendrie et 
a1.28 and Saunders et al.’ report gene frequencies in 
African-Americans more similar to those of Cau- 
casians. The cross-sectional analysis reported here es- 
tablishes this association only for similar populations 
of non-demented, community-dwelling elders. Infer- 
ences about association in this study would be threat- 
ened if the temporal relationship between exposure and 
outcome were not clear, but this is not the case for ge- 
netic  exposure^.^' Finally, bias is unlikely because we 
have used a cohort unselected for genotype or func- 
tional ability and assessed all subjects with equivalent 
measures. 
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